The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer

Show other versions (1)

Introduction: Breast cancers are divided into at least 4 sub Types on the Basis of gene expression profiles and expression of receptors as measured by IHC (Immunohistochemical). Triple negative breast cancer (TNBC) is more chemosensitive yet, it is much harder to detect than other sub types. At pres...

Full description

Bibliographic Details
Main Authors:	Seyyed AsadoLah Mousavi, Efat Mashhadi, Masud Iravani, Ardeshir Ghavamzade
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2013-01-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Chemotherapy CMF TNBC
Online Access:	http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/355/449

Similar Items

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
by: Seyyed Asadolah Mousavi, et al.
Published: (2013-03-01)

Adjuvant Chemotherapy of Early Stage Breast Cancer in Community-based Cancer Treatment Fields: CMF Compared with Anthracycline/Taxane-based Regimens
by: Narges Bayat Mokhtari, et al.
Published: (2017-04-01)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
by: Maj-Britt Jensen, et al.
Published: (2018-07-01)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
by: Wei Zhang, et al.
Published: (2023-04-01)

Construction and application of data-driven knowledge adjacency network for product CMF design
by: Chao LIU, et al.
Published: (2023-03-01)

Advances in Treatment of Triple Negative Breast Cancer
by: KANG Yikun, et al.
Published: (2022-08-01)

CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy
by: Marine Lemesle, et al.
Published: (2022-10-01)

Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis
by: Zijian Yang, et al.
Published: (2020-01-01)

MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients
by: Purwanto I, et al.
Published: (2021-01-01)

Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
by: Chen Y, et al.
Published: (2024-04-01)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
by: Liao Y, et al.
Published: (2018-09-01)

High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy
by: Hyelin Na, et al.
Published: (2019-11-01)

A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
by: Yijun Li, et al.
Published: (2022-06-01)

Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy
by: Ting Jiang, et al.
Published: (2023-06-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
by: Vrbavac Milenko, et al.
Published: (2002-01-01)

DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis
by: Shiyu Cao, et al.
Published: (2024-03-01)

Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression
by: Purwanto I, et al.
Published: (2023-07-01)

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation
by: Radhakrishnan Vishnubalaji, et al.
Published: (2022-09-01)

Adherance to approved protocol chemotherapy for breast cancer at Songklanagarind Hospital
by: W Achanond, et al.
Published: (2002-12-01)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
by: Kai Conrad Cecil Johnson, et al.
Published: (2023-06-01)

Co‐delivery CPT and PTX prodrug with a photo/thermo‐responsive nanoplatform for triple‐negative breast cancer therapy
by: Wenhui Zhou, et al.
Published: (2022-12-01)

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy
by: Heng Zhao, et al.
Published: (2023-09-01)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
by: Aiswarya Chaudhuri, et al.
Published: (2022-04-01)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
by: Jia-Yi Huang, et al.
Published: (2023-04-01)

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
by: Nityanand Srivastava, et al.
Published: (2023-07-01)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
by: Xueqiong Xun, et al.
Published: (2022-07-01)

Chondromyxoid fibroma of the mandible: A case report
by: Mohamed Elseyoufi, et al.
Published: (2021-01-01)

Rarest of the rare-male triple negative breast cancer
by: Haneesha Polavarapu, et al.
Published: (2022-01-01)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
by: Prarthna V. Bhardwaj, et al.
Published: (2023-08-01)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
by: Shi J, et al.
Published: (2020-09-01)

Moderate Exercise Modulates Tumor Metabolism of Triple-Negative Breast Cancer
by: Anderson Vulczak, et al.
Published: (2020-03-01)

The Roles of DNA Demethylases in Triple-Negative Breast Cancer
by: Shoghag Panjarian, et al.
Published: (2021-06-01)

Therapeutic landscape in mutational triple negative breast cancer
by: Yaqin Shi, et al.
Published: (2018-07-01)

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
by: Dakroub R, et al.
Published: (2023-11-01)

RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
by: Natalia B. Fernández, et al.
Published: (2023-01-01)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
by: Nadine S. van den Ende, et al.
Published: (2023-02-01)

Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis
by: Neha Pathak, et al.
Published: (2022-08-01)

Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
by: Cristina J. Dias, et al.
Published: (2021-12-01)

Research on the Effects of Chemotherapy on Survival Outcomes for Older Patients with Primary Triple-Negative Breast Cancer after Surgery: A Propensity Score Matching and Competing Risk Analysis of the SEER Database
by: Chongwu He, et al.
Published: (2023-03-01)

Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy
by: Lanjing Wei, et al.
Published: (2023-10-01)